



RFC1 repeat expansions in downbeat nystagmus syndromes: frequency and phenotypic profile

David Pellerin^{1,2} · Felix Heindl³ · Andreas Träschütz^{4,5} · Dan Rujescu⁶ · Annette M. Hartmann⁶ · Bernard Brais^{1,7,8} · Henry Houlden² · Claudia Dufke⁹ · Olaf Riess⁹ · Tobias Haack⁹ · Michael Strupp³ · Matthis Synofzik^{4,5} 

Received: 30 December 2023 / Revised: 26 January 2024 / Accepted: 27 January 2024
© The Author(s) 2024

Abstract

Objectives The cause of downbeat nystagmus (DBN) remains unknown in a substantial number of patients (“idiopathic”), although intronic GAA expansions in *FGF14* have recently been shown to account for almost 50% of yet idiopathic cases. Here, we hypothesized that biallelic *RFC1* expansions may also represent a recurrent cause of DBN syndrome.

Methods We genotyped the *RFC1* repeat and performed in-depth phenotyping in 203 patients with DBN, including 65 patients with idiopathic DBN, 102 patients carrying an *FGF14* GAA expansion, and 36 patients with presumed secondary DBN.

Results Biallelic *RFC1* AAGGG expansions were identified in 15/65 patients with idiopathic DBN (23%). None of the 102 GAA-*FGF14*-positive patients, but 2/36 (6%) of patients with presumed secondary DBN carried biallelic *RFC1* expansions. The DBN syndrome in *RFC1*-positive patients was characterized by additional cerebellar impairment in 100% (15/15), bilateral vestibulopathy (BVP) in 100% (15/15), and polyneuropathy in 80% (12/15) of cases. Compared to GAA-*FGF14*-positive and genetically unexplained patients, *RFC1*-positive patients had significantly more frequent neuropathic features on examination and BVP. Furthermore, vestibular function, as measured by the video head impulse test, was significantly more impaired in *RFC1*-positive patients.

Discussion Biallelic *RFC1* expansions are a common monogenic cause of DBN syndrome.

Keywords *FGF14* · *SCA27B* · GAA-FGF14 ataxia · CANVAS · Cerebellar ataxia · Bilateral vestibulopathy

Michael Strupp and Matthis Synofzik are shared last authors.

✉ Matthis Synofzik
matthis.synofzik@uni-tuebingen.de

¹ Department of Neurology and Neurosurgery, Montreal Neurological Hospital and Institute, McGill University, Montreal, QC, Canada

² Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology and The National Hospital for Neurology and Neurosurgery, University College London, London, UK

³ Department of Neurology and German Center for Vertigo and Balance Disorders, University Hospital, Ludwig-Maximilians University, Munich, Germany

⁴ Division Translational Genomics of Neurodegenerative Diseases, Hertie-Institute for Clinical Brain Research

and Center of Neurology, University of Tübingen, Tübingen, Germany

⁵ German Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany

⁶ Department of Psychiatry and Psychotherapy, Comprehensive Center for Clinical Neurosciences and Mental Health (C3NMH), Medical University of Vienna, Vienna, Austria

⁷ Department of Human Genetics, McGill University, Montreal, QC, Canada

⁸ Centre de Réadaptation Lucie-Bruneau, Montreal, QC, Canada

⁹ Institute of Medical Genetics and Applied Genomics, University of Tübingen, Tübingen, Germany

Introduction

Until recently, the cause of downbeat nystagmus (DBN) has remained unknown (“idiopathic”) in approximately 30% of cases [1]. However, intronic *FGF14* (GAA)_{≥250} repeat expansions, known to cause spinocerebellar ataxia 27B/*GAA-FGF14* disease [2, 3], were lately shown to account for almost 50% of previously unexplained DBN cases [4], suggesting that monogenic causes may be a recurrent cause of what has so far been considered “idiopathic” DBN.

In particular, biallelic *RFC1* repeat expansions may represent a common cause of “idiopathic” DBN syndrome given the anecdotal reports of DBN in *RFC1*-related disorder [5–9]. To test this hypothesis, we studied the frequency of *RFC1* repeat expansions in a cohort of patients with “idiopathic” DBN, characterized the phenotypic profile of the *RFC1*-related DBN syndrome, and compared it to that of the *GAA-FGF14*-related DBN syndrome.

Methods


We studied a series of 219 patients with suspected DBN of unknown etiology referred to the Department of Neurology or the German Center for Vertigo and Balance Disorders at the LMU Hospital in Munich, Germany, between 2012 and 2020. Patients underwent comprehensive etiologic evaluation of DBN syndrome and in-depth phenotyping as described previously [4]. Patients were excluded from the study if no or insufficient DNA was available for genetic screening ($n=5$) or if DBN was not objectified on examination ($n=11$) (Fig. 1). Of the remaining 203 patients with DBN, a presumed secondary cause of DBN—either acquired or genetic, but excluding *GAA-FGF14* disease—had previously been identified in 36 patients during

clinical and paraclinical evaluation, an *FGF14* (GAA)_{≥250} allele in 82 patients, and an *FGF14* (GAA)_{200–249} allele in 20 patients, yielding 65 patients with “idiopathic” DBN (Fig. 1). Patients carrying an *FGF14* (GAA)_{≥250} allele and a (GAA)_{200–249} allele were analyzed together due to recent evidence suggesting that (GAA)_{200–249} alleles may be associated with DBN, given their significant enrichment in patients with DBN and that the phenotype of (GAA)_{200–249}-*FGF14* patients closely mirrored that of (GAA)_{≥250}-*FGF14* patients [4]. All 203 patients with DBN were screened for *RFC1* AAGGG expansions as described previously [10]. Patients with a presumed secondary cause of DBN and *GAA-FGF14*-related DBN were not excluded from *RFC1* screening to explore the possibility of co-occurring diseases. Two patients with a presumed secondary cause of DBN (chronic alcohol use) who were found to carry biallelic *RFC1* repeat expansions were not included in the phenotypic analysis of the *RFC1*-related DBN syndrome cohort given the difficulty in determining the relative phenotypic contributions of chronic alcohol use and *RFC1* repeat expansions.

Deep phenotyping was performed by reassessing medical records using a standardized data sheet. Bilateral vestibulopathy (BVP) was diagnosed as per the consensus criteria of the Bárány Society requiring the documentation of bilaterally reduced or absent angular vestibular ocular reflex (VOR) function by caloric stimulation, video head impulse test (vHIT), or rotatory chair [11]. Polyneuropathy was diagnosed on nerve conduction studies (NCS), excluding focal entrapment neuropathies, or clinically defined by the combination of significantly decreased vibration sense at the ankles ($\leq 3/8$ on the Rydel–Seiffer scale) and decreased ankle reflexes [12].

This study was approved by the ethics committee of the LMU Munich and we obtained written informed consent from all the participants.

Fig. 1 Study flowchart of the recruitment of patients with DBN. *DBN* downbeat nystagmus



Results

Frequency of biallelic *RFC1* expansions

Biallelic *RFC1* AAGGG repeat expansions were identified in 15 of 65 (23%) patients with “idiopathic” DBN (Figs. 1 and 2A). Moreover, a high frequency of heterozygous *RFC1* repeat expansion carriers was observed in the “idiopathic” DBN cohort (12%, 8/65 patients / 6.2%, 8/130 allele frequency; compared to 0.7–6.5% carrier frequency in the general population [13]). A total of 50 patients remained unsolved after *RFC1* screening, and will be referred to onward as “genetically unexplained”. In addition, 2 of the 36 (6%) patients with presumed secondary DBN were found to carry biallelic *RFC1* AAGGG repeat expansions, while none of the 102 (GAA)_{≥200}-*FGF14*-positive patients did (Fig. 1).

Phenotypic characterization of the *RFC1*-related DBN syndrome

The frequency of biallelic *RFC1* repeat expansions stratified by DBN subgroups was 50% (3/6) for DBN plus cerebellar impairment and BVP, and 86% (12/14) for DBN plus cerebellar impairment, BVP, and polyneuropathy (Fig. 2B). None of the patients in the other DBN subgroups carried biallelic *RFC1* repeat expansions (Fig. 2B). Table 1 presents the clinical features of the *RFC1*-positive, (GAA)_{≥200}-*FGF14*-positive, and genetically unexplained DBN cohorts.

DBN occurred with cerebellar impairment in all 15 *RFC1*-positive patients, which was limited to the ocular motor system with typical cerebellar ocular motor signs (i.e., saccadic pursuit, dysmetric saccades, gaze-evoked nystagmus) in 5 patients (33%). Additional cerebellar ocular motor signs were observed in all *RFC1*-positive patients. Brain MRI showed global cerebellar atrophy in 27% (3/11) and




Fig. 2 Frequency of *RFC1* repeat expansions in DBN syndromes and progression of functional disability in the *RFC1*-related DBN syndrome. **A** Percentage of patients carrying biallelic *RFC1* AAGGG repeat expansions in a cohort of 65 patients with idiopathic downbeat nystagmus (DBN). **B** Percentage of patients carrying biallelic *RFC1* AAGGG repeat expansions in the phenotypic subgroups with (1) pure DBN, (2) DBN plus cerebellar impairment (DBN+C), (3) DBN plus cerebellar impairment and bilateral vestibulopathy (DBN+C+BVP), (4) DBN plus cerebellar impairment and polyneuropathy (DBN+C+N), and (5) DBN plus cerebellar impairment, BVP, and polyneuropathy (DBN+C+BVP+N). No patient with DBN plus isolated BVP or isolated neuropathy was identified among the idi-

opathic DBN cohort. **C** Disease duration at time of onset of regular use of walking aid and regular falls in the *RFC1*-positive patients with DBN. **D** Longitudinal intra-individual progression of functional impairment as assessed by the FARS functional disability stage relative to disease duration (35 observations from 11 patients with DBN carrying biallelic *RFC1* repeat expansions). Observations from the same patient are connected by a dotted line. The FARS functional stage assesses disability through a 7-point ordinal scale: 0=normal; 1=minimal signs on examination; 2=minimal disability; 3=mild disability; 4=moderate disability, requires a walker; 5=severe disability, confined but can navigate a wheelchair; 6=total disability

Table 1 Characteristics and discriminative features of the *RFC1*-related downbeat nystagmus syndrome

| | <i>RFC1</i> -positive group (<i>n</i> = 15) | (<i>GAA</i>) _{≥200} - <i>FGF14</i> - positive group (<i>n</i> = 102) | Genetically unexplained group (<i>n</i> = 50) | <i>RFC1</i> -positive vs <i>GAA-FGF14</i> - positive <i>p</i> value | <i>RFC1</i> -positive vs genetically unexplained <i>p</i> value |
|--|---|--|--|--|--|
| Male sex | 7 (74%) | 55 (54%) | 31 (62%) | – | – |
| Age at disease onset | 63.5 (44–78) | 67 (30–84) | 67 (17–88) | 0.080 | 0.262 |
| Disease duration | 7 (4–18) | 6 (0–26.5) | 4 (0–50) | 0.070 | 0.007 |
| Age at last examination | 72 (52–91) | 74.5 (40–92) | 72 (21–89) | 0.210 | 0.878 |
| Positive family history | 4/15 (27%) | 35/102 (34%) | 7/49 (14%) | 0.771 | 0.268 |
| FARS disability stage ^a | 3.25 (1.5–4) | 3 (1.5–5) | 2 (1–4) | 0.042 | 0.003 |
| History of falls | 8/9 (89%) | 35/64 (55%) | 10/23 (43%) | 0.072 | 0.044 |
| Regular use of walking aid | 7/14 (50%) | 19/99 (19%) | 7/49 (14%) | 0.017 | 0.009 |
| Symptoms | | | | | |
| Episodic symptoms | 0/14 (0%) | 11/100 (11%) | 18/49 (37%) | 0.354 | 0.006 |
| Postural instability | 15/15 (100%) | 101/101 (100%) | 50/50 (100%) | 1.000 | 1.000 |
| Visual disturbances | 9/15 (60%) | 55/102 (54%) | 20/50 (40%) | 0.784 | 0.238 |
| Fine motor impairment | 3/14 (21%) | 13/98 (13%) | 8/49 (16%) | 0.419 | 0.419 |
| Speech impairment | 3/15 (20%) | 17/100 (17%) | 8/48 (17%) | 0.723 | 0.714 |
| Swallowing difficulties | 1/15 (7%) | 7/100 (7%) | 4/49 (8%) | 1.000 | 1.000 |
| Sensory symptoms | 5/15 (33%) | 13/100 (13%) | 7/49 (14%) | 0.058 | 0.132 |
| Autonomic symptoms | 3/15 (20%) | 9/101 (9%) | 3/48 (6%) | 0.187 | 0.141 |
| Clinical signs | | | | | |
| Impaired balance/gait | 15/15 (100%) | 80/98 (82%) | 27/46 (59%) | 0.123 | 0.003 |
| Positive Romberg test | 12/13 (92%) | 48/87 (55%) | 15/38 (39%) | 0.013 | 0.001 |
| Cerebellar ocular motor signs | | | | | |
| Gaze-evoked nystagmus | 10/15 (67%) | 68/102 (67%) | 30/49 (61%) | 1.000 | 0.769 |
| Saccadic pursuit | 15/15 (100%) | 100/101 (99%) | 41/49 (84%) | 1.000 | 0.181 |
| Dysmetric saccades | 6/15 (40%) | 28/99 (28%) | 14/49 (29%) | 0.374 | 0.526 |
| Cerebellar ataxia | | | | | |
| Ataxia of upper limbs | 8/14 (57%) | 17/87 (20%) | 11/38 (29%) | 0.005 | 0.103 |
| Dysdiadochokinesia | 5/13 (38%) | 16/87 (18%) | 9/40 (22%) | 0.139 | 0.292 |
| Dysarthria | 4/15 (27%) | 14/99 (14%) | 6/45 (13%) | 0.252 | 0.250 |
| Neuropathy | | | | | |
| Impaired vibration at ankle (≤3/8) | 11/14 (79%) | 17/97 (18%) | 11/48 (23%) | < 0.001 | < 0.001 |
| Ankle hyporeflexia | 10/14 (71%) | 24/97 (25%) | 17/48 (35%) | < 0.001 | 0.030 |
| Pyramidal tract signs | 0/14 (0%) | 1/95 (1%) | 1/49 (2%) | 1.000 | 1.000 |
| Parkinsonism | 2/14 (14%) | 13/97 (13%) | 10/49 (20%) | 1.000 | 1.000 |
| MRI | | | | | |
| Disease duration at last MRI | 6 (5–15) | 4 (0–17) | 2 (–3–50) | 0.013 | 0.007 |
| Vermis atrophy | 4/11 (36%) | 9/71 (13%) | 5/33 (15%) | 0.068 | 0.195 |
| Cerebellar hemisphere atrophy | 3/11 (27%) | 5/71 (7%) | 4/33 (12%) | 0.070 | 0.341 |
| Brainstem atrophy | 1/11 (9%) | 0/70 (0%) | 1/33 (3%) | 0.136 | 0.442 |
| Nerve conduction studies | | | | | |
| Abnormal sural SNAP | 6/6 (100%) | 10/20 (50%) | 3/3 (100%) | 0.157 | 1.000 |
| Abnormal upper limb SNAP | 4/4 (100%) | 1/10 (10%) | 0/2 (0%) | 0.005 | 0.067 |
| Abnormal CMAP (any nerve) | 2/5 (40%) | 7/20 (35%) | 3/3 (100%) | 1.000 | 0.196 |
| Vestibular function evaluation—caloric stimulation, vHIT, rotatory chair | | | | | |
| Bilateral vestibulopathy | 15/15 (100%) | 11/97 (11%) | 5/45 (11%) | < 0.001 | < 0.001 |

Table 1 (continued)

| | <i>RFC1</i> -positive group (<i>n</i> = 15) | (<i>GAA</i>) _{≥200} - <i>FGF14</i> - positive group (<i>n</i> = 102) | Genetically unexplained group (<i>n</i> = 50) | <i>RFC1</i> -positive vs <i>GAA</i> - <i>FGF14</i> - positive <i>p</i> value | <i>RFC1</i> -positive vs genetically unexplained <i>p</i> value |
|---------------------------------------|---|--|--|---|--|
| VOR gain on vHIT in BVP—mean (±SD) | 0.15 (±0.11) | 0.39 (±0.15) | 0.50 (±0.07) | 0.004 | 0.036 |
| Response to 4-aminopyridine treatment | | | | | |
| Clinician-reported response | 1/6 (17%) | 33/41 (80%) | 4/9 (44%) | 0.004 | 0.580 |
| Patient-reported response | 1/7 (14%) | 32/54 (59%) | 1/11 (9%) | 0.041 | 1.000 |

Unless specified, data are reported as frequencies (percentages) for qualitative variables and median (range) for quantitative variables. Differences between groups were assessed with the non-parametric Mann–Whitney *U* test for continuous variables and the Fisher’s exact test for categorical variables. Bold values indicate statistically significant *p* values. Data on age at onset were missing for three patients in the *RFC1*-positive group, eleven patients in the (*GAA*)_{≥200}-*FGF14*-positive group, and five patients in the genetically unexplained group

BVP Bilateral vestibulopathy, *CMAP* Compound motor action potential, *FARS* Friedreich Ataxia Rating Scale, *SNAP* Sensory nerve action potential, *vHIT* Video head impulse test, *VOR* Vestibulo-ocular reflex

^aLast available *FARS* disability stage measured off 4-aminopyridine

isolated vermis atrophy in 9% (1/11) of patients. BVP was documented in all *RFC1*-positive patients by vHIT (*n* = 10) or caloric stimulation (*n* = 5). Polyneuropathy was identified in 12 of 15 (80%) *RFC1*-positive patients, and was diagnosed on NCS in six patients and clinically in six patients. Three patients had no evidence of neuropathic features on examination, though NCS were not available for these patients. The presence of chronic cough could not be reliably extracted from medical records, although it was documented in two patients in whom it developed more than 10 years before the onset of gait impairment.

Progression of functional disability in the *RFC1*-related DBN syndrome

A substantial proportion of *RFC1*-positive patients experienced regular falls (89%, 8/9), some of them as early as 2.5 years after disease onset (median disease duration at onset of regular falls, 4 years; range, 2.5–7.5). Furthermore, walking aids were used by 50% of patients (7/14) after a median disease duration of 6.5 years (range, 2.5–18) (Fig. 2C). At time of last examination, the median Friedreich Ataxia Rating Scale (*FARS*) functional stage was 3.25 (range, 1.5–4), indicating a mild-to-moderate disability (Fig. 2D).

Discriminative features of the *RFC1*-related DBN syndrome

Compared to (*GAA*)_{≥200}-*FGF14*-positive and genetically unexplained patients with DBN, *RFC1*-positive patients with DBN appeared more functionally impaired, as assessed by the *FARS* functional stage, history of regular falls and use of walking aids, and gait impairment on examination

(Table 1). However, the *RFC1*-positive DBN group also had a significantly longer disease duration compared to the genetically unexplained group (median, 7 vs 4 years; *p* = 0.007) and a trend toward longer disease duration compared to the (*GAA*)_{≥200}-*FGF14*-positive group (median, 7 vs 6 years; *p* = 0.070), which may account in part for the higher degree of functional impairment in the *RFC1*-positive group. Neuropathic features and proprioceptive dysfunction on examination were significantly more common in the *RFC1*-positive group (Table 1), in keeping with early and preferential involvement of dorsal root ganglia in that disease [14]. Vestibular impairment was also significantly more common and severe, as measured by VOR gains on vHIT, in *RFC1*-positive patients (*n* = 9) compared to (*GAA*)_{≥200}-*FGF14*-positive (*n* = 9) and genetically unexplained patients (*n* = 2) (Table 1).

Discussion

This study showed that biallelic *RFC1* AAGGG repeat expansions are a common monogenic cause of DBN syndrome, accounting for 23% of previously “idiopathic” DBN cases. Given this high frequency, genetic testing for *RFC1* repeat expansions may now become part of the diagnostic workup of patients with “idiopathic” DBN. Of note, since biallelic *RFC1* repeat expansions were also identified in 6% of patients who had a presumed secondary cause of DBN, genetic testing might need to be extended to this population as well—especially in the presence of other cerebellar signs, vestibular hypofunction, and/or polyneuropathy—given the implications for clinical management and eligibility for future clinical trials.

Our findings provide a deeper phenotypic characterization of the *RFC1*-related DBN syndrome by showing that they present along a continuum of involvement of the cerebellar, sensory, and vestibular systems. This confirms and extends previous notions of widespread neurodegeneration occurring in *RFC1*-related disorder [15]. Accordingly, no patient with pure DBN or DBN plus cerebellar impairment (without BVP and/or polyneuropathy) was found to carry biallelic *RFC1* repeat expansions, strengthening the observation that *RFC1*-related disorder is unlikely in presence of isolated cerebellar ataxia without sensory neuropathy [16]. The multisystemic involvement in the *RFC1*-positive DBN syndrome was further reflected by the significantly more common neuropathic features and proprioceptive dysfunction on examination as well as vestibular impairment—which was comparatively more severe—in this group compared to the $(GAA)_{\geq 200}$ -*FGF14*-positive and genetically unexplained groups. These phenotypic findings might help to raise clinical suspicion for *RFC1*-related disease over other monogenic causes of DBN, such as *GAA-FGF14* disease [4].

Our study also provides preliminary insights into the natural evolution of the *RFC1*-related DBN syndrome. A significant proportion of patients experienced regular falls and needed walking aids relatively early in the disease course, which is of importance for clinical management given the relevance for everyday living and as potentially highly meaningful outcomes in future treatment trials [17]. However, it remains to be established in larger, prospective cohort series if functional impairment progresses more rapidly in the *RFC1*-related DBN syndrome compared to the *GAA-FGF14*-related DBN syndrome, which would be in line with the higher degree of underlying multisystemic neurodegeneration in *RFC1*-related disease [15, 18].

Our study has several limitations. First, it is a single-centre retrospective study, which limited our ability to assess the evolution of multisystemic damage in the *RFC1*-positive DBN syndrome. Second, our study provides a conservative estimate of the real frequency of *RFC1*-related disorder in “idiopathic” DBN as it only screened for pathogenic AAGGG repeat motifs and not for truncating variants and other non-reference pathogenic motifs that have recently been shown to cause *RFC1*-related disorder [7, 19]. The elevated frequency of heterozygous *RFC1* repeat expansion carriers in our cohort (12%) raises the possibility that some of these patients may carry a novel variant in *trans* with the AAGGG expansion. Third, we were unable to objectify the presence of polyneuropathy—a universal feature of *RFC1*-related disorder [14, 15]—in all *RFC1*-positive patients as only 40% underwent NCS.

In conclusion, we showed that biallelic *RFC1* AAGGG repeat expansions are a recurrent monogenic cause of DBN syndrome.

Acknowledgements We thank the patients and their families for participating in this study. DP holds a Fellowship award from the Canadian Institutes of Health Research (CIHR).

Author contributions Design or conceptualization of the study: AT, MSt, and MSy. Acquisition of data: DP, FH, AT, DR, AMH, BB, HH, CD, OR, TH, MSt, and MSy. Analysis or interpretation of the data: DP, FH, AT, CD, TH, MSt, and MSy. Drafting or revising the manuscript for intellectual content: DP, FH, AT, DR, AMH, BB, HH, CD, OR, TH, MSt, and MSy.

Funding Open Access funding enabled and organized by Projekt DEAL. This work was supported by the Clinician Scientist program “PRECISE.net” funded by the Else Kröner-Fresenius-Stiftung (to AT, OR, and MSy), the grant 779257 “Solve-RD” from the European’s Union Horizon 2020 research and innovation program (to MSy), and the grant 01EO 1401 by the German Federal Ministry of Education and Research (BMBF) (to MSt). This work was also supported by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) N° 441409627, as part of the PROSPAX consortium under the frame of EJP RD, the European Joint Programme on Rare Diseases, under the EJP RD COFUND-EJP N° 825575 (to MSy and BB), the Fondation Groupe Monaco (to BB), the Montreal General Hospital Foundation (Grant PT79418 to BB), the Wellcome Trust (to HH), and the UK Medical Research Council (MRC) (to HH). The funders had no role in the conduct of this study.

Data availability Individual deidentified patient data may be shared at the request of any qualified investigator upon reasonable request.

Declarations

Conflicts of interest DP reports no disclosures. FH reports no disclosures. AT reports no disclosures. DR has received grant/research support from Janssen and Lundbeck; he has served as a consultant or on advisory boards for AC Immune, Janssen, Roche and Rovi and he has served on speakers’ bureaus of Janssen and Pharmgenetix. He also received honoraria from Gerot Lannacher, Janssen and Pharmgenetix, and travel support from Angelini and Janssen, all unrelated to the present manuscript. AMH reports no disclosures. BB reports no disclosures. HH reports no disclosures. CD reports no disclosures. OR reports no disclosures. TH reports no disclosures. MSt is Joint Chief Editor of the Journal of Neurology, Editor in Chief of Frontiers of Neuro-otology and Section Editor of F1000. He has received speakers honoraria from Abbott, Auris Medical, Biogen, Eisai, Grünenthal, GSK, Henning Pharma, Interacoustics, J&J, MSD, NeuroUpdate, Otometrics, Pierre-Fabre, TEVA, UCB, and Viatrix. He receives support for clinical studies from Decibel, U.S.A., Cure within Reach, U.S.A. and Heel, Germany. He distributes M-glasses and Positional vertigo App. He acts as a consultant for Abbott, AurisMedical, Bulbitech, Heel, IntraBio, Sensorion and Vertify. He is an investor and shareholder of IntraBio. All are unrelated to the present manuscript. MSy has received consultancy honoraria from Janssen, Ionis, Orphazyme, Servier, Reata, Biohaven, Zevra, Lilly, GenOrph, and AviadoBio, all unrelated to the present manuscript.

Ethical approval This study was approved by the ethics committee of the LMU Munich and was performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. Written informed consent from all the participants was obtained.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long

as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

References

- Tran TM, Lee MS, McClelland CM (2021) Downbeat nystagmus: a clinical review of diagnosis and management. *Curr Opin Ophthalmol* 32(6):504–514. <https://doi.org/10.1097/ico.0000000000000802>
- Pellerin D, Danzi MC, Wilke C et al (2023) Deep intronic FGF14 GAA repeat expansion in late-onset cerebellar ataxia. *N Engl J Med* 388(2):128–141. <https://doi.org/10.1056/NEJMoa2207406>
- Rafehi H, Read J, Szmulewicz DJ et al (2023) An intronic GAA repeat expansion in FGF14 causes the autosomal-dominant adult-onset ataxia SCA27B/ATX-FGF14. *Am J Hum Genet* 110(6):1018. <https://doi.org/10.1016/j.ajhg.2023.05.005>
- Pellerin D, Heindl F, Wilke C et al (2023) Intronic *FGF14* GAA repeat expansions are a common cause of downbeat nystagmus syndromes: frequency, phenotypic profile, and 4-aminopyridine treatment response. *MedRxiv*. <https://doi.org/10.1101/2023.07.30.23293380>
- Traschütz A, Heindl F, Bilal M et al (2023) Frequency and phenotype of RFC1 repeat expansions in bilateral vestibulopathy. *Neurology* 101(10):e1001–e1013. <https://doi.org/10.1212/wnl.0000000000207553>
- Terryn J, Van Eesbeek A, Vermeer S, Vandenberghe W (2020) The characteristic eye movement disorder of RFC1-linked CANVAS. *Mov Disord Clin Pract* 7(2):230–231. <https://doi.org/10.1002/mdc3.12896>
- Ronco R, Perini C, Currò R et al (2023) Truncating variants in RFC1 in cerebellar ataxia, neuropathy, and vestibular areflexia syndrome. *Neurology* 100(5):e543–e554. <https://doi.org/10.1212/wnl.0000000000201486>
- Scriba CK, Beecroft SJ, Clayton JS et al (2020) A novel RFC1 repeat motif (ACAGG) in two Asia-Pacific CANVAS families. *Brain* 143(10):2904–2910. <https://doi.org/10.1093/brain/awaa263>
- Borsche M, Thomsen M, Szmulewicz DJ et al (2023) Bilateral vestibulopathy in RFC1-positive CANVAS is distinctly different compared to FGF14-linked spinocerebellar ataxia 27B. *J Neurol* 271:1023–1027
- Cortese A, Simone R, Sullivan R et al (2019) Biallelic expansion of an intronic repeat in RFC1 is a common cause of late-onset ataxia. *Nat Genet* 51(4):649–658. <https://doi.org/10.1038/s41588-019-0372-4>
- Strupp M, Kim JS, Murofushi T et al (2017) Bilateral vestibulopathy: diagnostic criteria consensus document of the classification committee of the Bárány Society. *J Vestib Res* 27(4):177–189. <https://doi.org/10.3233/ves-170619>
- England JD, Gronseth GS, Franklin G et al (2005) Distal symmetric polyneuropathy: a definition for clinical research: report of the American Academy of Neurology, the American Association of Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. *Neurology* 64(2):199–207. <https://doi.org/10.1212/01.wnl.0000149522.32823.ea>
- Davies K, Szmulewicz DJ, Corben LA, Delatycki M, Lockhart PJ (2022) RFC1-related disease: molecular and clinical insights. *Neurol Genet* 8(5):e200016. <https://doi.org/10.1212/nxg.000000000200016>
- Currò R, Salvalaggio A, Tozza S et al (2021) RFC1 expansions are a common cause of idiopathic sensory neuropathy. *Brain* 144(5):1542–1550. <https://doi.org/10.1093/brain/awab072>
- Traschütz A, Cortese A, Reich S et al (2021) Natural history, phenotypic spectrum, and discriminative features of multisystemic RFC1 disease. *Neurology* 96(9):e1369–e1382. <https://doi.org/10.1212/wnl.0000000000011528>
- Hadjivassiliou M, Currò R, Beauchamp N et al (2023) Can CANVAS due to RFC1 biallelic expansions present with pure ataxia? *J Neurol Neurosurg Psychiatry*. <https://doi.org/10.1136/jnnp-2023-331381>
- Klockgether T, Ashizawa T, Brais B et al (2022) Paving the way toward meaningful trials in ataxias: an ataxia global initiative perspective. *Mov Disord* 37(6):1125–1130. <https://doi.org/10.1002/mds.29032>
- Wilke C, Pellerin D, Mengel D et al (2023) GAA-FGF14 ataxia (SCA27B): phenotypic profile, natural history progression and 4-aminopyridine treatment response. *Brain*. <https://doi.org/10.1093/brain/awad157>
- Dominik N, Magri S, Currò R et al (2023) Normal and pathogenic variation of RFC1 repeat expansions: implications for clinical diagnosis. *Brain*. <https://doi.org/10.1093/brain/awad240>